Abstract
Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported. A 66-year-old man was diagnosed with advanced RCC in 2005. The patient initially underwent nephrectomy, but subsequently the disease metastasized to the lung, lymph nodes, and pancreas. The patient received sorafenib 400 mg bid in a clinical trial. He experienced minimal and manageable adverse events and achieved stable disease (SD), which was maintained with sorafenib therapy for nearly 3 years before the development of liver metastases. The patient was then prescribed sunitinib, with which he also experienced SD for 1.2 years until disease progression prompted the initiation of third-line everolimus therapy, resulting in SD for another 8 months. The patient lived with stabilized RCC for 4.6 years with the use of these three sequential targeted therapies. First-line sorafenib monotherapy achieved a durable stable response and subsequent use of sunitinib and then everolimus permitted a return to SD after disease progression. The patient experienced minimal toxicity from the regimen, suggesting that it can be safely administered to elderly patients.
Similar content being viewed by others
References
Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.
Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8.
Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
Motzer R, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.
Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer. 2009;110:2321–6.
Schwandt A, et al. Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy [poster]. Presented at the American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium; February 26–28, 2009; Orlando, FL.
Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.
Horner MJ, et al. SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute; 2009.
Berdjis N, Hakenberg OW, Novotny V, Froehner M, Wirth MP. Treating renal cell cancer in the elderly. BJU Int. 2006;97:703–5.
Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol. 2009;69:64–72.
Eisen T, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454–63.
Escudier B, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280–9.
Hutson TE, et al. Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): data analysis from patients (pts) treated for over 1 year in the phase III TARGET study [abstract]. J Clin Oncol. 2009;27(Suppl):e16057.
Lamuraglia M, et al. Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: a prospective study. J Clin Oncol. 2005;23(16S):3069.
Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29–34.
Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442–5.
Acknowledgments
Financial support for this study was provided by Bayer Healthcare Pharmaceuticals, Inc. Writing support was provided by Ogilvy Healthworld and financed by Bayer. Dr Beck has received honoraria from Bayer and Pfizer for attending advisory boards and from Bayer, Pfizer, and Roche for participating in speaker bureaus. Dr Bellmunt has received honoraria from Bayer, Pfizer, Roche, Wyeth, and Novartis for consultancy and attending advisory boards, and from Bayer, Pfizer, and Roche for participating in speaker bureaus. Dr Escudier has received honoraria from Bayer, Pfizer, Roche, Novartis, and GSK for consultancy and attending advisory boards.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beck, J., Bellmunt, J. & Escudier, B. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Med Oncol 28, 1379–1383 (2011). https://doi.org/10.1007/s12032-010-9589-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-010-9589-x